This is a non-core endpoint: only basic statistics are computed.
See its core counterpart CD2_INSITU_LARYNX_EXALLC for full statistics.
Endpoint definition
↥
FinnGen phenotype data
392423 individuals
Apply sex-specific rule None
392423
Check conditions
not C3_LARYNX
391994
Check pre-conditions, main-only, mode, registry filters
Hospital Discharge: ICD-10
D02.0&
Hospital discharge: ICD-9
2310
Cause of death: ICD-10
D02.0&
Cause of death: ICD-9
2310
Cancer registry: Topography ICD-O-3
C32
Cancer registry: Morphology ICD-O-3
ANY
Cancer registry: Behaviour codes
2
3 out of 7 registries used, show all original rules.
41
Check minimum number of events None
41
Include endpoints None
41
Remove individuals based on genotype QC
41
CD2_INSITU_LARYNX
Control definitions
Controls for this endpoint are individuals that are not cases.
Extra metadata
Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF9
Parent code in ICD-10
D02
Name in latin
Carcinoma in situ bronchi
Show upset plot detailing case counts by codes
Or the full data table
Similar endpoints
↥List of similar endpoints to
Carcinoma in situ of larynx
based on the number of shared cases.
Broader endpoints:
- Carcinoma in situ of larynx (controls excluding all cancers)
- Carcinoma in situ of middle ear and respiratory system (controls excluding all cancers)
- Carcinoma in situ of middle ear and respiratory system
- In situ neoplasms
- In situ neoplasms (controls excluding all cancers)
Narrower endpoints:
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 41 | 10 | 31 |
| Unadjusted prevalence (%) | 0.01 | 0.00 | 0.02 |
| Mean age at first event (years) | 65.87 | 50.98 | 70.68 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: CD2_INSITU_LARYNX – Carcinoma in situ of larynx
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Carcinoma in situ of larynx
↥Endpoint not on priority list, no data to show.